Open access
Aug 2026
Antisense oligonucleotide selection scheme for rare Duchenne muscular dystrophy mutations: Application to DMD exon 16 skipping
The feasibility of developing a safe and effective lead compound with efficient exon 16 skipping, favorable pharmacokinetic and safety profiles, able to rescue dystrophic transcriptomic and proteomic signatures is demonstrated.
Marine Geoffroy-Guiraud, C. Beley, Stephany Campuzano et al.
· Molecular Therapy: Nucleic A... · 0 citations